Literature DB >> 25093740

Perspectives on sudden death prevention in hypertrophic cardiomyopathy.

Georgios K Efthimiadis1, Thomas Zegkos, Soultana Meditskou, Stavros Hadjimiltiades.   

Abstract

Sudden death (SD) is the most dramatic event in hypertrophic cardiomyopathy (HCM), often representing the first clinical manifestation of the disease, and the first concern of the clinicians who take care of such patients. HCM is now recognized as the primary cause of SD in young persons (<35 years of age), including trained athletes. Current data in unselected HCM patient populations report an approximate 0.7% per year incidence of SD, with the total cardiovascular mortality being around 1.4% annually. This review, incorporating contemporary research findings, addresses the major aspects of SD and its prevention in HCM. The traditional risk factors and other controversial risk factors for SD or the arbitrators for that event are thoroughly analyzed and the need for the development of a unique and accurate factor for SD risk stratification is discussed. Rather than enumerating clinical studies and guidelines, challenging problems concerning all aspects of SD in HCM, are critically appraised, highlighting current speculations and recommending future directions.

Entities:  

Mesh:

Year:  2014        PMID: 25093740     DOI: 10.1097/CRD.0000000000000017

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  2 in total

1.  The predictive value of left ventricular and left atrial mechanics for atrial fibrillation and heart failure in hypertrophic cardiomyopathy: a prospective cohort study.

Authors:  Thomas Zegkos; Dimitris Ntelios; Despoina Parcharidou; Sotiris Katranas; Theofilos Panagiotidis; Christos A Papanastasiou; Efstratios Karagiannidis; Pavlos Rouskas; Vassilis Vassilikos; Haralampos Karvounis; Georgios K Efthimiadis
Journal:  Int J Cardiovasc Imaging       Date:  2021-04-05       Impact factor: 2.357

2.  Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: What has Changed in The Guidelines?

Authors:  Liliana Reis; Rogerio Teixeira; Andreia Fernandes; Inês Almeida; Marta Madeira; Joana Silva; Ana Botelho; João Pais; José Nascimento; Lino Gonçalves
Journal:  Arq Bras Cardiol       Date:  2018-06       Impact factor: 2.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.